CD19 and acute lymphoblastic leukemia: Particularly encouraging results were demonstrated when infused CAR T-cells redirected against the CD19 antigen in patients with relapsed/refractory acute lymphoblastic leukemia resulted in a high-rate of long-lasting complete remissions.